Evidence map›Paper›PMID 38163998›Full record

SynthesisThe Journal of clinical endocrinology and metabolism2024

Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines.

Victoria Fitz, Sandro Graca, Shruthi Mahalingaiah, Jing Liu, Lily Lai, Ali Butt, Mike Armour, Vibhuti Rao, Dhevaksha Naidoo, Alison Maunder and 10 more

Erratum issued Registry-linked trialOpen access · hybridAbstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The Journal of clinical endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07629895 (Comparison of Efficacy of Myo-Inositol Alone With Myo-Inositol Plus Alpha-Lactalbumin on Reproductive and Metabolic Parameters in Polycystic Ovarian Syndrome), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
22.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07629895 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Comparison of Efficacy of Myo-Inositol Alone With Myo-Inositol Plus Alpha-Lactalbumin on Reproductive and Metabolic Parameters in Polycystic Ovarian Syndrome

TypeinterventionalSponsorQuaid-e-Azam Medical CollegeRan2026 to 2027Enrolled82ConditionsPolycystic Ovary Syndrome (PCOS)ArmsMyo-inositol, Alpha-Lactalbumin
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 6 countries.

Victoria FitzDivision of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, USA.
Sandro GracaSchool of Health and Society, Faculty of Education, Health and Wellbeing, University of Wolverhampton, Wolverhampton WV1 1LY, UK.
Shruthi MahalingaiahDivision of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, USA.
Jing LiuNICM Health Research Institute, Western Sydney University, Penrith 2751, Australia.
Lily LaiPrimary Care Research Centre, University of Southampton, Southampton SO17 1BJ, UK.
Ali ButtNICM Health Research Institute, Western Sydney University, Penrith 2751, Australia.
Mike ArmourNICM Health Research Institute, Western Sydney University, Penrith 2751, Australia.
Vibhuti RaoNICM Health Research Institute, Western Sydney University, Penrith 2751, Australia.
Dhevaksha NaidooNICM Health Research Institute, Western Sydney University, Penrith 2751, Australia.
Alison MaunderNICM Health Research Institute, Western Sydney University, Penrith 2751, Australia.
Guoyan YangNICM Health Research Institute, Western Sydney University, Penrith 2751, Australia.
Vaishnavi VaddiparthiNICM Health Research Institute, Western Sydney University, Penrith 2751, Australia.
Selma F WitchelUPMC Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Alexia PenaDiscipline of Paediatrics, The University of Adelaide and Robinson Research Institute, Adelaide 5005, Australia.
Poli Mara SpritzerGynecological Endocrinology Unit, Division of Endocrinology, Hospital de Clinicas de Porto Alegre; Department of Physiology, Universidade Federal do Rio Grande do Sul, Rio Grande do Sul 91509-900, Brazil.
Rong LiDepartment of OB & GYN, Reproductive Medical Center, Peking University Third Hospital, Beijing 100191, China.ORCID 0000-0003-0305-5579
Chau TayMonash Centre for Health Research and Implementation, Monash University, Clayton 3800, Australia.
Aya MousaMonash Centre for Health Research and Implementation, Monash University, Clayton 3800, Australia.ORCID 0000-0002-7356-4523
Helena TeedeMonash Centre for Health Research and Implementation, Monash University, Clayton 3800, Australia.ORCID 0000-0001-7609-577X
Carolyn EeNICM Health Research Institute, Western Sydney University, Penrith 2751, Australia.ORCID 0000-0002-3363-9199
Western Sydney University · AUMonash University · AUMassachusetts General Hospital · USFlinders University · AUNIHR Southampton Biomedical Research Centre · GBPeking University · CNThe University of Adelaide · AUUniversidade Federal do Rio Grande do Sul · BRUniversity of Pittsburgh · USUniversity of Wolverhampton · GB

Funding

Australian National Health and Medical Research CouncilCentre for Research Excellence in Women's Health in Reproductive LifeCRE WHIRLNHMRCNHMRC CRE WHIRL
6 · The paper itself

Abstract

contextInsulin resistance is common in women with polycystic ovary syndrome (PCOS). Inositol may have insulin sensitizing effects; however, its efficacy in the management of PCOS remains indeterminate.

objectiveTo inform the 2023 international evidence-based guidelines in PCOS, this systematic review and meta-analysis evaluated the efficacy of inositol, alone or in combination with other therapies, in the management of PCOS. DATA SOURCES: Medline, PsycInfo, EMBASE, All EBM, and CINAHL from inception until August 2022. STUDY SELECTION: Thirty trials (n = 2230; 1093 intervention, 1137 control), with 19 pooled in meta-analyses were included. DATA EXTRACTION: Data were extracted for hormonal, metabolic, lipids, psychological, anthropometric, reproductive outcomes, and adverse effects by 1 reviewer, independently verified by a second. DATA SYNTHESIS: Thirteen comparisons were assessed, with 3 in meta-analyses. Evidence suggests benefits for myo-inositol or D-chiro-inositol (DCI) for some metabolic measures and potential benefits from DCI for ovulation, but inositol may have no effect on other outcomes. Metformin may improve waist-hip ratio and hirsutism compared to inositol, but there is likely no difference for reproductive outcomes, and the evidence is very uncertain for body mass indexI. Myo-inositol likely causes fewer gastrointestinal adverse events compared with metformin; however, these are typically mild and self-limited.

conclusionThe evidence supporting the use of inositol in the management of PCOS is limited and inconclusive. Clinicians and their patients should consider the uncertainty of the evidence together with individual values and preferences when engaging in shared decision-making regarding the use of inositol for PCOS.

Indexed as

InositolPolycystic Ovary SyndromeEvidence-Based MedicineFemaleHumansInsulin ResistancePractice Guidelines as TopicInositolinositolnutrientspolycystic ovary syndrome

Identifiers

PMID38163998
PMCPMC11099481
OpenAlexW4390508316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.